Advertisement

Cancer Immunology, Immunotherapy

, Volume 57, Issue 7, pp 1039–1051 | Cite as

Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma

  • P. Hersey
  • G. M. Halliday
  • M. L. Farrelly
  • C. DeSilva
  • M. Lett
  • S. W. Menzies
Original Article

Abstract

Background

In the present study, we have examined whether treatment of patients with metastatic melanoma with matured dendritic cell (DC) vaccines with or without low dose IL-2 may improve treatment outcomes.

Methods

Sixteen patients received DC vaccines (DCs) sensitized with autologous melanoma lysates and 18 patients received DCs sensitized with peptides from gp100, MART-1, tyrosinase, MAGE-3.A2, MAGE-A10 and NA17. IL-2 was given subcutaneously (sc) at 1 MU/m2 on the second day after each injection for 5–14 days in half of each group. DCs were given by intranodal injection.

Results

There were 2 partial responses (PR) and 3 with stable disease (SD) in the nine patients receiving DCs + peptides + IL-2, and 1 PR and 1 SD in nine patients treated with DCs + peptides without IL-2. There were only two patients with SD in the group receiving DCs + autologous lysates and no IL-2. Median overall survival for all patients was very good at 18.5 months but this was most probably due to selection of a favourable group of patients for the study. There was no significant difference in survival between the groups by log rank analysis. Treatment was not associated with significant side effects. The quality and yield of the DCs in the preparations were generally good.

Conclusions

We conclude that mature DC preparations may be superior to immature DC preparations for presentation of melanoma peptides and that IL-2 may increase clinical responses to the DCs plus peptides. However, in our view the low response rates do not justify the cost and complexity of this treatment approach.

Keywords

Melanoma Dendritic cells Vaccines Interleukin-2 Melanoma peptides Clinical responses 

Notes

Acknowledgments

This study was supported by grants from the National Health and Medical Research Council and the Sydney Melanoma Foundation. We wish to thank Professor Thompson and Drs. Quinn, Spillane, Shannon and Saw at the Sydney Melanoma Unit for their support.

References

  1. 1.
    Anichini A, Scarito A, Molla A, Parmiani G, Mortarini R (2003) Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common γ-chain cytokines. J Immunol 171:2134–2141PubMedGoogle Scholar
  2. 2.
    Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738–4745PubMedCrossRefGoogle Scholar
  3. 3.
    de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ (2003a) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9:5091–5100PubMedGoogle Scholar
  4. 4.
    de Vries IJM, Krooshoop JEB, Scharenborg NM, Lesterhuis WJ, Diepstra JHS, van Muijen GNP, Strijk SP, Ruers TJ, Boerman OC, Oyen WJG, Adema GJ, Punt CJA, Figdor CG (2003b) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63:12–17PubMedGoogle Scholar
  5. 5.
    Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233–238PubMedCrossRefGoogle Scholar
  6. 6.
    Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethe B, Jotereau F, Boon T (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 183:1173–1183PubMedCrossRefGoogle Scholar
  7. 7.
    Hersey P (1997) Melanoma vaccines. Prospects for the treatment of melanoma. Expert Opin Investig Drugs 6:267–277PubMedCrossRefGoogle Scholar
  8. 8.
    Hersey P (2002) Advances in the non-surgical treatment of melanoma. Expert Opin Investig Drugs 11:75–85PubMedCrossRefGoogle Scholar
  9. 9.
    Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, De Silva C, Lett M (2004) Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53:125–134PubMedCrossRefGoogle Scholar
  10. 10.
    Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H (2005) Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 54:208–218PubMedCrossRefGoogle Scholar
  11. 11.
    Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A (1999) Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol 162:6849–6854PubMedGoogle Scholar
  12. 12.
    Jaeger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54–62CrossRefGoogle Scholar
  13. 13.
    Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243–251PubMedCrossRefGoogle Scholar
  14. 14.
    Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135–3142PubMedCrossRefGoogle Scholar
  15. 15.
    Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192:1213–1222PubMedCrossRefGoogle Scholar
  16. 16.
    Luft T, Jefford M, Luetjens P, Toy T, Hochrein H, Masterman KA, Maliszewski C, Shortman K, Cebon J, Maraskovsky E (2002) Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 100:1362–1372PubMedCrossRefGoogle Scholar
  17. 17.
    Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA (1996) Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 2:669–677PubMedGoogle Scholar
  18. 18.
    Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK (1998) Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res 58:2965–2968PubMedGoogle Scholar
  19. 19.
    Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura T, Maekawa T, Yamamoto A, Shimada S, Saida T, Kawakami Y, Asano S, Tani K, Takahashi TA, Yamashita N (2003) Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mautre dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 13:521–530PubMedCrossRefGoogle Scholar
  20. 20.
    Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMedCrossRefGoogle Scholar
  21. 21.
    Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJM, Jongmans W, Adema GJ, Debruyne FMJ, de Mulder PH, Oosterwijk E, Mulders PFA (2002) Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunol 25:500–508Google Scholar
  22. 22.
    Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539–2548PubMedGoogle Scholar
  23. 23.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327PubMedCrossRefGoogle Scholar
  24. 24.
    Scandella E, Men Y, Gillessen S, Forster R, Groettrup M (2002) Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100:1354–1361PubMedCrossRefGoogle Scholar
  25. 25.
    Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tuttenberg A, Becker JC, Keikavoussi P, Kampgen E, Schuler G; DC study group of the DeCOG (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563–570PubMedCrossRefGoogle Scholar
  26. 26.
    Shimizu K, Fields RC, Giedlin M, Mule JJ (1999) Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci, USA 96:2268–2273PubMedCrossRefGoogle Scholar
  27. 27.
    Shrikant P, Mescher MF (2002) Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J Immunol 169:1753–1759PubMedGoogle Scholar
  28. 28.
    Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527–534PubMedCrossRefGoogle Scholar
  29. 29.
    Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016–4026PubMedCrossRefGoogle Scholar
  30. 30.
    Sotomayor EM, Borrello I, Tubb E, Rattis F-M, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI (1999) Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5:780–787PubMedCrossRefGoogle Scholar
  31. 31.
    Tham EL, Shrikant P, Mescher MF (2002) Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response. J Immunol 168:1190–1197PubMedGoogle Scholar
  32. 32.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  33. 33.
    Valmori D, Fonteneau J-F, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini J-C, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750–1758PubMedGoogle Scholar
  34. 34.
    Walden P (2007) Therapeutic vaccination for the treatment of malignant melanoma. Recent Results Cancer Res 176:219–227PubMedGoogle Scholar
  35. 35.
    Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD (2000) Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 192:1637–1643PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • P. Hersey
    • 1
  • G. M. Halliday
    • 2
    • 3
  • M. L. Farrelly
    • 1
  • C. DeSilva
    • 4
  • M. Lett
    • 4
  • S. W. Menzies
    • 4
  1. 1.Oncology and Immunology UnitNewcastleAustralia
  2. 2.Department of DermatologyUniversity of SydneySydneyAustralia
  3. 3.Melanoma and Skin Cancer InstituteSydney UniversitySydneyAustralia
  4. 4.Sydney Melanoma UnitRoyal Prince Alfred HospitalCamperdownAustralia

Personalised recommendations